Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenues:
Product sales	$ 43,663	$ 67,266	$ 120,739	$ 161,991
Contracts and grants	15,099	6,720	44,697	20,933
Total revenues	58,762	73,986	165,436	182,924
Operating expenses:
Cost of product sales	10,706	11,532	27,843	30,116
Research and development	29,216	21,156	95,456	59,680
Selling, general and administrative	17,432	20,693	56,028	54,534
Income (loss) from operations	1,408	20,605	(13,891)	38,594
Other income (expense):
Interest income	22	38	81	802
Interest expense	0	0	0	0
Other income (expense), net	37	(1,003)	(9)	(1,012)
Total other income (expense)	59	(965)	72	(210)
Income (loss) before provision for (benefit from) income taxes	1,467	19,640	(13,819)	38,384
Provision for (benefit from) income taxes	1,604	7,696	(3,032)	15,088
Net income (loss)	(137)	11,944	(10,787)	23,296
Net loss attributable to noncontrolling interests	1,686	1,176	5,149	2,155
Net income (loss) attributable to Emergent BioSolutions Inc.	$ 1,549	$ 13,120	$ (5,638)	$ 25,451
Earnings (loss) per share - basic	$ 0.04	$ 0.42	$ (0.16)	$ 0.82
Earnings (loss) per share - diluted	$ 0.04	$ 0.41	$ (0.16)	$ 0.80
Weighted-average number of shares - basic	35,855,217	31,301,796	35,552,900	31,094,616
Weighted-average number of shares - diluted	36,447,933	32,113,313	35,552,900	31,816,900